High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains

Journal of Infectious Diseases

Volumn 187, Issue 11, 2003, Pages 1709-1716

  Prunier, Anne Laure ^a   Malbruny, Brigitte ^a   Laurans, Muriel ^a   Brouard, Jacques ^a   Duhamel, Jean François ^a   Leclercq, Roland ^a,b  

^a CHU CÔTE DE NACRE   (France)

^b CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; ERYTHROMYCIN; MACROLIDE; RIBOSOME RNA; RIFAMPICIN; ROXITHROMYCIN; STREPTOMYCIN;

ADAPTATION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; GENE DELETION; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; INCIDENCE; NONHUMAN; PATIENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RIBOSOME; SEQUENCE ANALYSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ADENOSINE TRIPHOSPHATASES; ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CYSTIC FIBROSIS; DNA, RIBOSOMAL; DNA-BINDING PROTEINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI PROTEINS; FEMALE; HUMANS; MACROLIDES; MALE; MUTATION; MUTS DNA MISMATCH-BINDING PROTEIN; PHENOTYPE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 0037864230     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/374937     Document Type: Article

References (36)

1. Davis PB. Cystic fibrosis. Pediatr Rev 2001; 22:257-64.
2. Govan JR, Nelson JW. Microbiology of lung infection in cystic fibrosis. Br Med Bull 1992; 48:912-30.
3. Tateda K, Ishii Y, Matsumoto T, et al. Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob Agents Chemother 1996; 40:2271-5.
4. CASFM. Technical recommendations for in vitro susceptibility testing. Clin Microbiol Infect 1996; 2(Suppl 1):S11-25.
5. Fleiss JL. Statistical methods for rates and populations. 2nd ed. New York: Wiley, 1981.
6. Aubry-Damon H, Legrand P, Brun-Buisson C, Astier A, Soussy CJ, Leclercq R. Reemergence of gentamicin-susceptible strains of methicillin-resistant Staphylococcus aureus: roles of an infection control program and changes in aminoglycoside use. Clin Infect Dis 1997; 25:647-53.
7. Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33:2233-9.
8. Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L. Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother 1996; 40:2562-6.
9. Canu A, Malbruny B, Coquemont M, Davies TA, Appelbaum PC, Leclercq R. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycln in Streptococcus pneumoniae. Antimicrob Agents Chemother 2002; 46:125-31.
10. Prunier AL, Malbruny B, Tande D, Picard B, Leclercq R. Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides. Antimicrob Agents Chemother 2002; 46:3054-6.
11. Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 1975; 98:503-17.
12. Hansen LH, Mauvais P, Douthwaite S. The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol Microbiol 1999; 31:623-31.
13. Vester B, Douthwaite S, Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob Agents Chemother 2001; 45:1-12.
14. Kuroda M, Ohta T, Uchiyama I, et al. Whole genome sequencing of methicillin-resistant Staphylococcus aureus. Lancet 2001; 357:1225-40.
15. Unge J, Berg A, Al Kharadaghi S, et al. The crystal structure of ribosomal protein L22 from Thermus thermophilus: insights into the mechanism of erythromycin resistance. Structure 1998; 6:1577-86.
16. Tait-Kamradt A, Davies T, Appelbaum PC, et al. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother 2000; 44:3395-401.
17. Aubry-Damon H, Soussy CJ, Courvalin P. Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1998; 42:2590-4.
18. LeClerc JE, Li B, Payne WL, Cebula TA. High mutations frequencies among Escherichia coli and Salmonella pathogens. Science 1996; 274:1208-11.
19. Horst JP, Wu TH, Marinus MG. Escherichia coli mutator genes. Trends Microbiol 1999; 7:29-36.
20. Baba T, Takeuchi F, Kuroda M, et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002; 359:1819-27.
21. Lamers MH, Perrakis A, Enzlin JH, Winterwerp HH, de Wind N, Sixma TK. The crystal structure of DNA mismatch repair protein MutS binding to a GXT mismatch. Nature 2000; 407:711-7.
22. Lina G, Quaglia A, Reverdy ME, Leclercq R, Vandenesch F, Etienne J. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. Antimicrob Agents Chemother 1999; 43:1062-6.
23. Schmitz FJ, Sadurski R, Kray A, et al. Prevalence of macrolide-resistance genes in Staphylococcus aureus and Enterococcus faecium isolates from 24 European university hospitals. J Antimicrob Chemother 2000; 45:891-4.
24. Eady EA, Ross JI, Tipper JL, Walters CE, Cove JH, Noble WC. Distribution of genes encoding erythromycin ribosomal methylases and an erythromycin efflux pump in epidemiologically distinct groups of staphylococci. J Antimicrob Chemother 1993; 31:211-7.
25. Martinez JL, Baquero F. Mutation frequencies and antibiotic resistance. Antimicrob Agents Chemother 2000; 44:1771-7.
26. Giraud A, Matic I, Radman M, Fons M, Taddei F. Mutator bacteria as a risk factor in treatment of infectious diseases. Antimicrob Agents Chemother 2002; 46:863-5.
27. Alonso A, Campanario E, Martinez JL. Emergence of multidrug-resistant mutants is increased under antibiotic selective pressure in Pseudomonas aeruginosa. Microbiology 1999; 145:2857-62.
28. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288:1251-4.
29. Taddei F, Radman M, Maynard-Smith J, Toupance B, Gouyon PH, Godelle B. Role of mutator alleles in adaptive evolution. Nature 1997; 387:700-2.
30. Ren L, Rahman MS, Humayun MZ. Escherichia coli cells exposed to streptomycin display a mutator phenotype. J Bacteriol 1999; 181:1043-4.
31. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57:212-6.
32. Elphick HE, Tan A. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst Rev 2000; 1:CD002007.
33. Mouton JW. Combination therapy as a tool to prevent emergence of bacterial resistance. Infection 1999; 27(Suppl 2):S24-8.
34. Smith BT, Grossman AD, Walker GC. Visualization of mismatch repair in bacterial cells. Mol Cell 2001; 8:1197-206.
35. O'Neill AJ, Chopra I. Insertional inactivation of mutS in Staphylococcus aureus reveals potential for elevated mutation frequencies, although the prevalence of mutators in clinical isolates is low. J Antimicrob Chemother 2002; 50:161-9.
36. Funchain P, Yeung A, Stewart JL, Lin R, Slupska MM, Miller JH. The consequences of growth of a mutator strain of Escherichia coli as measured by loss of function among multiple gene targets and loss of fitness. Genetics 2000; 154:959-70.